Azithromycin (COPD Exacerbation Prophylaxis)
Brand names: Zithromax, Azithromycin (generic)
Azithromycin is a macrolide antibiotic used here as long-term prophylaxis to reduce the frequency of exacerbations in selected patients with COPD, typically those with frequent exacerbations despite optimised inhaled therapy.
The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.
The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Azithromycin.
Clinical monograph
How it works
It binds the bacterial 50S ribosomal subunit to inhibit protein synthesis, and in this setting is thought to act partly through anti-inflammatory and immunomodulatory effects rather than antibacterial action alone.
Prescribing in practice
- Most important: it prolongs the QT interval and risks serious arrhythmia, so obtain a baseline ECG and review concurrent QT-prolonging drugs before starting long-term use, per MHRA advice.
- Exclude active non-tuberculous mycobacterial infection and consider sputum culture before initiating prophylaxis, as long-term macrolide monotherapy risks driving resistance.
- Reserve for non-smokers or those who have stopped smoking, as the exacerbation benefit is reduced in current smokers; review the indication periodically.
Monitoring
Monitor with baseline and periodic ECG for QT prolongation, liver function, and hearing, and review continued need at intervals.
Counselling the patient
- Report palpitations, fainting, or new hearing problems promptly.
- Tell any prescriber you are taking long-term azithromycin before starting other medicines.
Evidence & guidelines
Long-term macrolide prophylaxis is supported by NICE and trials such as those underpinning reduced COPD exacerbation rates in selected frequent exacerbators.
Reference: NICE NG115 COPD; ALBERT Trial (Albert et al, NEJM 2011); BTS Bronchiectasis Guidelines 2019; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Caprini Score for VTE Risk (2005) · VTE Risk
- SIRS Criteria and Sepsis Definition · Sepsis
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Acute Otitis Media — Antibiotic or Observation (AAP 2013) · Otitis Media
- Neutrophil-to-Lymphocyte Ratio (NLR) · Inflammatory Markers
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024